• Skip to main content
  • Skip to secondary menu
  • Skip to footer
Clinical Digital Resource Collaborative

Clinical Digital Resource Collaborative

Designed and developed in the North East and North Cumbria by local GPs

National Health Service
  • Home
  • About Us
  • Our Team
  • What We Offer
    • Primary Care
    • Commercial
  • Resources
    • Referral Forms
    • EMIS Resources
      • CDRC EMIS Access
      • EMIS: Long Term Condition (LTC) Management
      • Medicine Management
        • EMIS: Precision Monitoring Template
        • EMIS: DMARDs and High Risk Drugs
        • EMIS: Safe Prescribing of Opioids / Opiates
      • Specialties
        • EMIS: Cancer
        • EMIS Cardiovascular Overview
          • EMIS: Cardiovascular Disease (AF, CHD, HF, Hypertension)
          • EMIS: Cardiovascular Disease (CVD) Prevention
          • Lipids, Familial Hypercholesterolaemia (FH), PCSK9i & Inclisiran Guide for EMIS
          • EMIS: Peripheral Arterial Disease Guide
        • EMIS Diabetes Overview
          • EMIS Diabetes
          • EMIS: Diabetes Technology
        • EMIS: Care for Frail Patients
        • EMIS: Haematology
        • Infection
          • EMIS: Infections Guide
          • EMIS: Blood Borne Virus (BBV)
        • EMIS: Learning Disabilities
        • EMIS: Neurology Guide
        • EMIS: NHS Health Checks
        • EMIS: Paediatric Assessment
        • EMIS: Palliative Care and End of Life
        • EMIS Renal Overview
          • Chronic Kidney Disease (CKD) – EMIS
        • Respiratory Overview
          • EMIS Respiratory Resources
          • BeatAsthma+ Guide for EMIS
        • EMIS: Rheumatology
    • SystmOne Resources
      • National Early Warning Score 2 (NEWS2) Guide for SystmOne
      • Getting Started
        • Getting Started – Access
        • Getting Started – How-To’s
      • SystmOne Administration
      • Contract Management
        • Impact and Investment Fund (IIF)
        • Quality and Outcomes Framework (QOF) Guidance for 2023/24
        • SystmOne: NHS Health Checks
        • SystmOne: WorkWell Local Enhanced Service
      • Long Term Condition Management
        • Call/ Recall System
        • Recall Recovery System
        • Care Planning
      • SystmOne Safeguarding System
        • Safeguarding Adults
        • Safeguarding At Risk of Harming Others
        • Safeguarding Family/Household Cause for Concern
        • Safeguarding Children
      • Medicine Management
        • Drugs Requiring Monitoring System
        • SystmOne: Antibiotics Prescribing & Optimisation
        • Safety & Reviews
        • Safe Prescribing of Opioids / Opiates
        • Safe Prescribing of NSAIDS
        • Safe Prescribing of Lithium
        • Safe Prescribing of Valproate
        • Safe Prescribing of Corticosteroids / Steroids
      • Specialties
        • Blood Borne Virus (BBV) Test Alert for SystmOne
        • BeatAsthma+ Guide for SystmOne
        • Cancer Overview
          • Cancer
          • Suspected Cancer
        • Cardiovascular Overview
          • Cardiology Results
          • Hypertension & Blood Pressure
          • SystmOne Heart Failure
          • Atrial Fibrillation (AF)
          • Integrated CVD Prevention
          • Peripheral Arterial Disease (PAD)
        • SystmOne Diabetes Overview
          • SystmOne Diabetes
          • SystmOne: Diabetes Technology
          • SystmOne Diabetic Kidney Disease
        • ENT Infections
        • Geriatrics Overview
          • SystmOne: Care for Frail Patients
          • Comprehensive Geriatric Assessment
          • Co-ordinated Care
        • Haematology
        • Infection Overview
        • Learning Disabilities
        • Lifestyle
        • Lipids, Familial Hypercholesterolaemia, PCSK9i & Inclisiran Overview
          • Lipids, Familial Hypercholesterolaemia (FH), PCSK9i & Inclisiran Report Guide for SystmOne
          • Lipids Protocols
          • Lipid Management Templates
          • Lipid QoF Support
          • Screening for Familial Hypercholesterolaemia
          • Aetiology of Abnormal Lipids
          • Lipids Strategy
        • MSK Referral Management
        • Neurology
        • Obesity Resources
        • Ophthalmology
        • Palliative Care and End of Life
        • SystmOne Renal/Urology Overview
          • Chronic Kidney Disease (CKD)
        • Respiratory Overview
          • Respiratory Resources
          • Respiratory Infections
        • Rheumatology Overview
          • SystmOne: Osteoporosis and Fragility Fractures
          • Bone Health
      • SystmOne: Weight Management
      • Women’s Health Overview
        • Gynaecology Resource Overview
          • Cervical Screening
          • Contraception
          • Prolapse
        • 6-8 Week Postnatal Check
      • Vaccination Overview
        • COVID-19 Resources- SystmOne
        • Influenza Vaccination SystmOne
        • Meningitis B Vaccination
        • Meningitis ACWY Vaccination
        • Pneumococcal Vaccination
        • RSV Vaccination SystmOne
        • Shingles Vaccination
  • FAQs
  • News and Events
    • Demonstrations
    • Events
      • Recordings
    • Articles
    • Conference abstracts
  • Contact us
You are here: Home / Resources / SystmOne Resource Centre / SystmOne Specialties / Lipids, Familial Hypercholesterolaemia, PCSK9i & Inclisiran Overview / Lipid Management Templates

Lipid Management Templates

CDRC Lipid Management Templates can be used for accurate assessment, coding and management of patients to help meet best practice, QoF and PCN DES IIF indicators.

Lipid Details Template

The Lipid Details template provides an overview of lipid assessment and management. 

How to Access

In the search bar located in the bottom left-hand corner on SystmOne, type ‘Lipid Details – CDRC’ and select the this template:

Alternatively, press F12 and search for ‘Lipid Details – CDRC’, this will return the aforementioned template.

Lipids Homepage

QRlSK2 
Lipids Lipid Results 
Lipids 
QRlSK2 calculator 
03 
03 
03 
Lipid Targets Exceptions 
NICE Lipid Pathway 
FH Screening References Lipids (legacy) 
PRIMARY PREVENTION likely to be recommended 
23 
4 Feb 2021 
Feb 2021 
3 2021 
Feb 2021 
3 2021 
Feb 2021 
4 Feb 2021 
QRlSK2 cardiovascular disease 10 year risk sc 
23 34 % 
serum HDL cholesterol level (44P5J (SNOMECI 
1 3 mmol/L 
Serum triglyceride levels [XE2qg) (SNOMED: 10 
113 mmol/L 
Serum non high density lipoprotein cholesterol In 3Æ mmol/L 
serum cholesterol level [XE2eO) (SNOMEO: 10 
5M mmol/L 
serum LOL cholesterol level (4496) (SNOMED 
31 mmol/L 
Target serum non high density lipoprotein cholest.„ 23 mmol/l 
Lipid Targets 
Over the counter statin therapy 
Lipid Lowering Medication 
Lipid Exceptions 
Lipid Lowering Declined 
Lipid Lowering Not Indicated 
On max tolerated lipid lowering 
Lipid Lowering Checklist 
FH Screening 
Atorvastatin 20mg tablets 26 Mar take tan 
Lipid target NOT achieved 
lgsep 2017 statin declined oxalil) (SNOMED: 1343g6000) 
2 
Details 
Lipid Resuts Table 
A Medication Timeline 
Lipid Resuts wth Lipid Rx 
Expand 
Finished by 
WILKINSON, Susan (Sister) (Nurse Access Role) [04 Feb 2021 
Lipid Narrative 
Lipid Lowering Treatment 
Told to avoid drink grapefruit 
juice 
Asked to report muscle pain, 
tenderness or weakness 
Asked to report 
breathlessness, dry cough 
Pregnancy, contraception, 
breastfeeding discussed 
Atorvastatin 
Yes 
Yes 
Yes 
Not applicable

Template Contents 

Column 1 Column 2 Column 3 
 A summary of the indications for lipid lowering  The button will open a screen showing more details e.g.  y OCS Lipids Risk - Conditions 
16 Jan 2018 QRISK2 cardiovascular disease 10 year risk score (SNOMED: 71 8087004) 
NO clear record of CHD 
NO clear record of code for CKD 
No record of diabetes 
NO clear record of code for strokeyTlA 
Close 
log7%  
Link to QRISK2 calculator or space to record manual QRISK2 Most recently recorded QRISK2 score  
Link to page to allow creation of lipid target Most recent cholesterol (and triglyceride if present) targets.  
Tickbox to record that patient is taking statin over the counter Link to Lipid Lowering Medication template which provides more details on lipid lowering therapies Current repeat lipid lowering Warnings and alerts, including: Consider starting lipid lowering Poor concordance/compliance Consider setting lipid target Target not achieved Consider statin intensification Link to the Medication Timeline which shows a schematic of all previous medication Link to Lipids Results and Lipid Rx which shows a list of lipid lowering medication and lipid results so response to treatment and concordance can be assessed eg.  15 Jan 2018 
2018 
15 Jan 2018 
2018 
serum LDL cholesterol level (44P6J (SNOMED: 1 0221 gl 0000001 00) 
Serum non high density lipoprotein cholesterol level [XabE1) (SNOMED: 
serum HDL cholesterol level (44P5J (SNOMED: 1 005681 0000001 07) 
serum cholesterol level (SNOMED: 1 005671 0000001 05) 
10061 glo 
27 mmol/L 
4 mmol/L 
1 2 mmol/L 
51 mmol/L 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
2g May 2018 Serum non high density lipoprotein cholesterol level [XabE1) (SNOMEC) 
2g May 2018 serum HDL cholesterol level (44P5J (SNOMED: 1005681 0000001 07) 
May 2018 serum cholesterol level (SNOMED: 10056710000001 05) 
2g May 2018 serum LDL cholesterol level (4496) (SNOMED: 10221 el 0000001 00) 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
05 Jun 201g 
serum HDL cholesterol level (4495) (SNOMED: 1 005681 0000001 07) 
05 dun 201g 
Serum non high density lipoprotein cholesterol level [XabE1) (SNOMED: 
05 Jun 201g 
serum LDL cholesterol level (44P6J (SNOMED: 1 0221 gl 0000001 00) 
05 dun 201g 
serum cholesterol level (SNOMED: 1 005671 0000001 05) 
Atorvastatin 20mg tablets 
take one daily 
06 Feb 2018 
06 Mar 2018 
26 Mar 2018 
24 Apr 2018 
21 May 2018 
10061g10 1 
1 2 mmol/L 
2Æ mmol/L 
1M mmol/L 
2018 
13 dui 2018 
15 Aug 2018 
17 sep 2018 
16 Oct 2018 
13 Nov 2018 
06 2018 
08 201g 
05 Feb 201'? 
05 Mar 201g 
26 Mar 
24 Apr 201 g 
23 May 201'? 
14 mmol/L 
10061g10 2 mmoI/L 
1 3 mmol/L 
34 mmol/L 
18 dun   
Link to Exceptions Page Button to record that lipid lowering has been declined – this will also check to ensure that all lipid lowering is declined as well as just statins Button to record that lipid lowering is not indicated – this will also check to ensure that all lipid lowering is not indicated as well as just statins Tick box to record that the patient is on maximally tolerated lipid lowering therapy Most recent codes indicating that lipid lowering is not appropriate e.g. declined, not indicated, not tolerated.   A warning will be displayed if the patient has a S1 ADR to statins recorded but not a Snomed code A button to show all previous lipid lowering exception codes and S1 lipid lowering ADR information. e.g. OCS Lipid Lowering - Exceptions (statin) + SI ADRs 
RECORD of ADR to statin(s) - NOT OOF CODED 
Drug Allergies 
22 2013 SIMVASTATIN 
Notes 
Entered 
Muscle aches at 80mg 
22 Aug 201 3 og:53 by FORBES, Gareth (Dr) (General Medical Practitioner)  OCS Lipid Lowering - Exceptions (statin) + SI ADRs 
RECORD of ADR to statin(s) - NOT OOF CODED 
02 Mar 2011 
statin not indicated (SNOMED: 1 343g1 005) 
Drug Allergies 
b 26 Novigga 
Entered 
28 Apr2015 
Notes 
Entered 
FLUCLOXACILLIN 
26 Nov 1 get by ASTLEY, David (Dr) 
ATORVASTATIN 
generally unwell, mood changes 
28 Apr 201 5 og:1 6 by GREENFIELD, Claire (Dr) (Clinical Practitioner Access Role)  
Button to run lipid lowering checklist – this protocol runs a series of checks looking at drug indication, dosing, lipid targets, drug interactions and provides a checklist for key information about the prescribing with information for the patient.  Lipid Narrative 
Lipid Lowering Treatment 
Atorvastatin 
Fluvastatin 
Pravastatin 
ROsuvastatin 
Simvastatin 
Ezetimibe 
Praluent 
Repatha 
Asked to report muscle pain, tenderness or weakness 
O Yes 
O No 
O Not known 
Asked to report breathlessness, dry cough 
O Yes 
O No 
O Not known 
Pregnancy, contraception, breastfeeding discussed 
O Yes 
O No 
Not known  The latest contents of the lipid lowering checklist  
Link to Familial Hypercholesterolaemia screening tab   

Lipids Results Page

Lipids Lipid Results 
Total Choi 
05 Jan 2005 
06 Jan 2006 
11 2010 
2011 
06 dui 2015 
03 Feb 2021 
Lipid Targets Exceptions 
LDL Choi 
05 dan 2005 
06 Jan 2006 
11 2010 
2011 
06 dui 2015 
03 Feb 2021 
FH Screening References 
HDL Choi 
Lipids (legacy) 
Non HDL Choi 
03 Feb 2021 
Triglycerides 
1 33 
05 dan 2005 
06 Jan 2006 
11 Jan 2010 
10 Jun 2011 
06 dui 2015 
03 Feb 2021 
058 
23 
05 dan 2005 
06 Jan 2006 
11 2010 
2011 
06 dui 2015 
03 Feb 2021 
More information about targets 
Non HDL Cholesterol (if not recorded) 
Target non-HDL cholesterol 
wth date 
04 Feb 2021 
mmol/ 
Target serum non high density lipoprotein cholesterol level (XaXhVL„23 mmol/l 
Non-HDL cholesterol = Total cholesterol - HDL cholesterol 
Usual target is 60% of pre-treatment non-HDL cholesterol 
Lipid Resuts Table 
Medication Timeline 
Lipid Rx Issues 
Lipid Resuts wth Lipid Rx 
Expand 
Calculator

This page shows previous lipid results so trends can be followed.   

Buttons in the top right provide links to: 

  • The TPP lipids tables and graph function. 
Data 
Preset 
Settings Graph 
All Lipid Tests 
Z] Only show readings that the patient has at least one of 
Edit Presets 
Serum choleste 
Date 
05 dan 2005 
06 dan 2006 
11 2010 
10 dun 2011 
06 dui 2015 
03 Feb 2021 
Serum LDL choL„ Serum choleste„ Serum HDL chu 
1 33 
Serum triglyceride levels 
058 
23
  • The Medication Timeline 
  • A list of all issued lipid lowering medication 
  • A list of all lipid results with lipid lowering medication 

The bottom panel shows the most recent lipid target. 

There is a box to record historic non-HDL cholesterol results.  Historically, these were often not sent with lipid results.  They can be calculated retrospectively but subtracting HDL cholesterol from total cholesterol and recording the resulting value with the date of the original result. 

The final box is to record the target non-HDL cholesterol.  This is the target reading recommended by NICE for the majority of patients.  Alternative readings may be needed in specialist cases (e.g. LDL-C in familial hypercholesterolaemia) – More details about targets can be found on the Lipid Targets Page. 

There is a calculator to help calculate the target non-HDL cholesterol 

Lipids Targets Page

Lipids Lipid Results Lipid Targets 
Lipid Targets 
Exceptions 
FH Screening References Lipids (legacy) 
In general targets for lipid modification are 
Most People (primary and secondary prevention) 
40% reduction in non-HDL cholesterol 
Calculator* 
Target non-HDL cholesterol 
Target LDL cholesterol 
Familial Hypercholesterolaemia 
mmol/ 
mmol/ 
50% reduction in LDL cholesterol 
4 Feb 2021 
Target serum non high density lipoprot.„ 
23 mmol/l 
Expand 
Other targets may be used in more specialist settings 
Target total cholesterol 
Target HDL cholesterol 
Target triglyceride 
mmol/ 
mmol/ 
mmol/

Exceptions Page

Lipids Lipid Results Lipid Targets Exceptions FH Screening 
Lipid Lowering Exceptions 
References 
Lipids (legacy) 
NO record of general exception to all lipid lowering 
Lipid Lowering Exceptions 
Expiring Statin Exceptions 
Expiring exceptions 
need to be added 
every OOF year 
Max tolerated lipid lowerim 
Lipid lowering declined 
Lipid lowering not indicated 
Lipid lowering contraindicated 
Max tolerated lipid lowerin„ 
Statin declined 
Statin not indicated 
[3 Statins contraindicated 
10 Jun 2011 
2011 
Wig sep 2017 
statin declined oxalil) (SNOMED: 1343 
Statin not indicated (Xallg) (SNOMED: 
statin declined rxalll) (SNOMED: 1 
Persisting Statin Exceptions [3 Simvastatin adverse 
Pravastatin adverse 
Fluvastatin adverse reaction 
[3 Statin adverse reaction 
For atorvastatin and rosuvastatin, use the bottom code with free text 
Record Allergy or Senstivty 
NO clear record of lipid lowering ADR 
Drug Allergies 
Expand 
Expand 
Expand 
Expand

Familial Hypercholesterolaemia (FH) Screening Page

Exceptions FH Screening Aetiology Lipid Review 
Lipids Lipid Results Lipid Targets 
Screening For Familial Hypercholesterolaemia 
Record FHx Cardiovascular 
0 ll Record FHx Hyperlipdaemia 
Family history of tendinous xanthoma in I st degree relative 
Te ndinous xanthoma 
Arcus of cornea 
First degree rel With coronaryNascular disease <55y (M) , <60y (F) 
First degree relative with LDL-C above 95th centile 
First degree relative With tendon xanthoma and/or arcus cornealis 
Has a child With LDL-C>g5th centile at age <18y 
Premature coronary heal disease <55y (men), <60y (women) 
Premature cerebral/peripheral vascular disease <55y (M), <60y (F) 
Tendinous xanthomata 
Arcus cornealis before 45 years 
LDL-Cholesterol (pre-treatment) 
Dutch Lipid Clinic Network diag crit fam hyperchol 
Go to Hyperlipidaemia Aetiology Page 
Referral to lipid clinic 
Seen n lipid clinic 
LOL receptor genotyping 
References Lipids (legacy) 
Family History Ischaemic Heart Disease 
No clear family history of high lipids 
NO clear record of FHx of tendinous xanthoma 
NO clear record of tendinous xanthoma 
NO clear record of arcus 
26 Feb 2007 Angina 
NO record of strokeJTlA OOF code 
24 Aug 2021 Serum LDL cholesterol le 
NO clear record of DCLNS 
-8 Definite FH 
6-8 Probable FH 
3-5 Possible FH 
<3FH Unlikely 
Potential secondary hyperlipidaemia - Diabetes 
NO clear record of lipid clinic involvement 
CVO 
0 ll <-FHx Lipids 
A <-Stroke 
Lipid Resuts 
<Expand 
Expand

The Screening for FH Page facilitates the calculation of a Dutch Lipid Clinic Network score.  The information in the middle panel helps to provide the information needed to complete the score, with the buttons on the right allowing the user to expand those panels to see fuller/more detailed information. 

Lower on the template, factors that might contribute to secondary hyperlipidaemia are shown e.g. obesity, alcohol consumption, diabetes, nephrotic syndrome. 

Lipid Lowering Template

The Lipid Lowering template facilitates safe and effective lipid lowering therapy treatments.

How to Access

In the search bar located in the bottom left-hand corner on SystmOne, type ‘Lipid Lowering – CDRC’ and select the following template:

Alternatively, press F12 and search for ‘Lipid Lowering – CDRC’, this will return the aforementioned template.

Lipid Lowering Template Home Page

The Lipid Lowering page provides an overview of lipid lowering treatment.

Lipid Lowering Atonxastatin 
Fluvastatin Pravastatin Rosuvastatin Simvastatin Ezetimibe PCSKgi Statin Potency 
Lipid Lowering 
NICE Lipid Pathway OU Vpid Pathway! 
PRIMARY PREVENTION likely to be recommended 
A O Details 
Q QRISK 
03 
2 Calculator 
Statin Cates Plot 
0 
PIL Statin Patient Decision Aid 
Calculate Target Non HDL-C 
Target Non HDL-C 
Statin offered 
Lipid Lowering Declined 
Lipid Lowering Not Indicated 
Default Rx 
Primary prevention - atorvastatin 20mg 
Secondary prevention - atorvastatin 80mg 
Atorvastatin 
Fluvastatin 
Pravastatin 
Rosuvastatin 
Simvastatin 
Ezetimibe 
PCSKgi 
Lipid Lowering Checklist 
4 Feb 2021 
Feb 2021 
3 2021 
3 2021 
3 2021 
3 2021 
04 Feb 2021 
QRlSK2 cardiovascular disease 10 year risk sc 
serum HDL cholesterol level (44P5J (SNOMECI 
serum triglyceride levels (SNOMEO: 10 
Serum non high density lipoprotein cholesterol 
serum cholesterol level [XE2eO) (SNOMEO: 10 
serum LDL cholesterol level (44P6J (SNOMED 
23 
1 3 mmol/L 
113 mmol/L 
3Æ mmol/L 
5M mmol/L 
31 mmol/L 
Target serum non high density lipoprotein cholest.„ 23 mmol/l 
Atorvastatin 20mg tablets 
26 Mar take 
Lipid target NOT achieved 
lg sep 2017 statin declined oxalil) (SNOMED: 1343g6000) 
Lipid Lowering Checklist 
2 
04 Feb 2021 14:11 
Lipid Resuts Table 
A Medication Timeline 
Lipid Resuts wth Lipid Rx 
Expand 
Entered by 
Finished by 
WILKINSON, Susan (Sister) (Nurse Access Role) 
WILKINSON, Susan (Sister) (Nurse Access Role) [04 Feb 2021 
Lipid Narrative 
Lipid Lowering Treatment 
Told to avoid drink grapefruit 
juice 
Asked to report muscle pain, 
tenderness or weakness 
Asked to report 
breathlessness, dry cough 
Atorvastatin 
Yes 
Yes 
Yes
Column 1 Column 2 Column 3 
 As summary of the indications for lipid lowering  The button will open a screen showing more details e.g.  y OCS Lipids Risk - Conditions 
16 Jan 2018 QRISK2 cardiovascular disease 10 year risk score (SNOMED: 71 8087004) 
NO clear record of CHD 
NO clear record of code for CKD 
No record of diabetes 
NO clear record of code for strokeyTlA 
Close 
log7%  
Link to QRISK2 calculator Most recently recorded QRISK2 score  
Link to website with statin Cates plots – this webpage will be opened with the patient’s most recent QRISK2 score. Link to the NICE Statin Patient Decision Aid Most recent lipid results Link to TPP lipid table/graph 
Button to calculate a target non-HDL cholesterol, based on achieving a 40% reduction in non-HDL choletesterol Box to manually enter target non-HDL cholesterol, if needed, e.g. if the most recent non-HDL cholesterol is ‘on treatment’. Most recent cholesterol (and triglyceride if present) targets.  
 Current repeat lipid lowering Warnings and alerts, including: Consider starting lipid lowering Poor concordance/compliance Consider setting lipid target Target not achieved Consider statin intensification Link to the Medication Timeline which shows a schematic of all previous medication Link to Lipids Results and Lipid Rx which shows a list of lipid lowering medication and lipid results so response to treatment and concordance can be assessed eg.  15 Jan 2018 
2018 
15 Jan 2018 
2018 
serum LDL cholesterol level (44P6J (SNOMED: 1 0221 gl 0000001 00) 
Serum non high density lipoprotein cholesterol level [XabE1) (SNOMED: 
serum HDL cholesterol level (44P5J (SNOMED: 1 005681 0000001 07) 
serum cholesterol level (SNOMED: 1 005671 0000001 05) 
10061 glo 
27 mmol/L 
4 mmol/L 
1 2 mmol/L 
51 mmol/L 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
2g May 2018 Serum non high density lipoprotein cholesterol level [XabE1) (SNOMEC) 
2g May 2018 serum HDL cholesterol level (44P5J (SNOMED: 1005681 0000001 07) 
May 2018 serum cholesterol level (SNOMED: 10056710000001 05) 
2g May 2018 serum LDL cholesterol level (4496) (SNOMED: 10221 el 0000001 00) 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
Atorvastatin 20mg tablets 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
take one daily 
05 Jun 201g 
serum HDL cholesterol level (4495) (SNOMED: 1 005681 0000001 07) 
05 dun 201g 
Serum non high density lipoprotein cholesterol level [XabE1) (SNOMED: 
05 Jun 201g 
serum LDL cholesterol level (44P6J (SNOMED: 1 0221 gl 0000001 00) 
05 dun 201g 
serum cholesterol level (SNOMED: 1 005671 0000001 05) 
Atorvastatin 20mg tablets 
take one daily 
06 Feb 2018 
06 Mar 2018 
26 Mar 2018 
24 Apr 2018 
21 May 2018 
10061g10 1 
1 2 mmol/L 
2Æ mmol/L 
1M mmol/L 
2018 
13 dui 2018 
15 Aug 2018 
17 sep 2018 
16 Oct 2018 
13 Nov 2018 
06 2018 
08 201g 
05 Feb 201'? 
05 Mar 201g 
26 Mar 
24 Apr 201 g 
23 May 201'? 
14 mmol/L 
10061g10 2 mmoI/L 
1 3 mmol/L 
34 mmol/L 
18 dun   
Tickbox for statin offered Buttons to record that lipid lowering if declined or not indicated – the protocol which runs from this button will check if all lipid lowering therapy is declined or not indicated or just statins. Most recent codes indicating that lipid lowering is not appropriate e.g. declined, not indicated, not tolerated.   A warning will be displayed if the patient has a S1 ADR to statins recorded but not a Snomed code A button to show all previous lipid lowering exception codes and S1 lipid lowering ADR information. e.g. OCS Lipid Lowering - Exceptions (statin) + SI ADRs 
RECORD of ADR to statin(s) - NOT OOF CODED 
Drug Allergies 
22 2013 SIMVASTATIN 
Notes 
Entered 
Muscle aches at 80mg 
22 Aug 201 3 og:53 by FORBES, Gareth (Dr) (General Medical Practitioner)  OCS Lipid Lowering - Exceptions (statin) + SI ADRs 
RECORD of ADR to statin(s) - NOT OOF CODED 
02 Mar 2011 
statin not indicated (SNOMED: 1 343g1 005) 
Drug Allergies 
b 26 Novigga 
Entered 
28 Apr2015 
Notes 
Entered 
FLUCLOXACILLIN 
26 Nov 1 get by ASTLEY, David (Dr) 
ATORVASTATIN 
generally unwell, mood changes 
28 Apr 201 5 og:1 6 by GREENFIELD, Claire (Dr) (Clinical Practitioner Access Role)  
Links to tabs for individual lipid lowering medication Button to run lipid lowering checklist – this protocol runs a series of checks looking at drug indication, dosing, lipid targets, drug interactions and provides a checklist for key information about the prescribing with information for the patient.  Lipid Narrative 
Lipid Lowering Treatment 
Atorvastatin 
Fluvastatin 
Pravastatin 
ROsuvastatin 
Simvastatin 
Ezetimibe 
Praluent 
Repatha 
Asked to report muscle pain, tenderness or weakness 
O Yes 
O No 
O Not known 
Asked to report breathlessness, dry cough 
O Yes 
O No 
O Not known 
Pregnancy, contraception, breastfeeding discussed 
O Yes 
O No 
Not known  The latest contents of the lipid lowering checklist  

Pages for for Individual Drugs

Pages for the individual drugs show key prescribing and safety information.  Key information (such as renal function) is shown in the middle panel, along with warnings about potential safety issues and interactions. 

There are buttons for: 

  • Creating new repeat of atorvastatin 20mg 
  • Creating new repeat of a different dose of atorvastatin 
  • Creating statin PIL 
  • Creating a scheduled task for checking lipids and LFTs in 3m (for routine monitoring after initiation) 
  • Running the lipid lowering checklist 
Lipid Lowering Atonxastatin 
Atorvastatin 
Moderate Potency 10mg 
High Potency 20, 40, 80mg 
Renal 
Avoid doses >20mg if eGFR 
Caution 
Fluvastatin 
-30 
Pravastatin 
Rosuvastatin Simvastatin Ezetimibe PCSKgi Statin Potency 
Has record of a HYPERLIPIDAEMIA 
PRIMARY PREVENTION likely to be recommended 
23 Mar 200g 
UBS cardiovascular disease risk -20% up to 30% ov next 10 
Atorvastatin 20mg tablets 04 Jun taken 28 t 
NO clear record of lipid lowering ADRs or exceptions 
Drug Allergies 
GFR calculated abbreviated MORD 
Serum alanine aminotransferase level 
AST serum level 
Serum creatine kinase level 
Alcohol intake 
Details 
Lipid ResutsyFx 
Expand 
Expand 
Amiodarone, ditliazem, dronedarone, sacubitril, verapamil 
Bezaflbrate, ciproflbrate, ezetimibe, fenoflbrate 
Grapefruitjuice 
Leflunomide, teriflunamide 
Fluconazole, miconazole, itraconazole, posaconazole 
Erythromycin 
Avoid'Contraindicated 
Clarithromycin 
Gemflbrozil 
Ciclosporin (and do not use doses above 10mg) 
Doses above 20mg with certain HIV drugs 
New repeat of Atorvastatin 20mg tablets 
New Repeat of other dose 
PIL Statin 
Scheduled Task - lipids and LFTs in 3m 
Lipid Lowering Checklist 
87 mLJmin/1 73m 
15 iu/L 
lg iu/L 
107 iu/L 
28 unitsmeek 
03 Mar 2021 
03 Mar 2021 
23 Mar 200g 
03 Apr 2007 
04 Nov 2020 
! CAUTION - ON DILTIAZEM - RISK OF INTERACTION 
DCS Lipid Lowering - Checklist view has no data for patient

Statin Potency Page 

Shows statin potencies 

Statin Potency 
ow potency- Fluvastatin 20 40; Pravastatin 10 20 40; Simvastatin 10 
Moderate Potency - Fluvastatin 80; Simvastatin 20 j 40; Atonxastatin 10; Rosuvastatin 5mg 
High Potency- Simvastatin 80*; Atonxastatin 20 j 40 j 80; Rosuvastatin 10 20 j 40 
* Advice from the MHRA: there is an increased risk of myopathy associated with high-dose (80 mg) simvastatirL The 80 mg 
dose should be considered only in patients with severe hypercholesterolaemia and high risk of cardiovascular 
complications who have not achieved their treatment goals on lower doses, when the benefits are expected to outweigh 
the potential risk. 
NICE Grouping

Footer

Follow us on social media

  • Facebook
  • LinkedIn
  • Twitter
contact-cdrc@healthinnovationnenc.org.uk
This website is operated by Health Innovation North East and North Cumbria. Suite A, 2nd Floor, 1 Citygate, Gallowgate, Newcastle upon Tyne NE1 4WH. Registered in England and Wales, Company Registration Number: 08727658
  • Terms of Reference
  • Privacy policy
  • Terms of use
  • Cookie Policy (UK)
  • Accessibility Statement

Copyright © 2026 Clinical Digital Resource Collaborative

Manage Consent
We use cookies to optimise our website and our service.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}